ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/TIGIT
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/TIGIT
32
trial(s) found.
NCT06868277
Advanced
Phase 3
Not yet recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) (
ARTEMIDELung04
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06727565
Advanced
Phase 2
Recruiting
A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma (
VELOCITY-HNSCC
)
Carboplatin
Domvanalimab
Paclitaxel
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
platinum-based antineoplastic agent
taxane
+ anti-TIGIT monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06357533
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (
TROPION-Lung10
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4215 - Southport - Gold Coast University Hospital (WITHDRAWN)
NCT06109779
Curative
Phase 3
Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) (
D7025C00001
)
bispecific PD-1/TIGIT antibody
placebo
Biliary tract cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06003621
Advanced
Phase 2
Recruiting
A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours. (
MoST-TAP
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
NOT Non-small cell lung cancer
Solid tumour
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2640 - Albury - Border Medical Oncology Research Unit
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
4700 - Rockhampton - Rockhampton Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4870 - Cairns - Cairns Base Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05908786
Curative
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC) (
GO44457
)
Atezolizumab
Bevacizumab
Tiragolumab
Tobemstomig
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-TIGIT monoclonal antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05676931
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer (
EDGE-Lung
)
CD73 inhibitor
Docetaxel
Domvanalimab
Quemliclustat
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,CD73-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
taxane
+ anti-TIGIT monoclonal antibody
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
QLD
4217 - Benowa - Pindara Private Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05286801
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (
NCI-2022-01992
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
+ bispecific PD-1/TIGIT antibody
Biliary tract cancer
Breast cancer
Endometrial cancer
Ovarian cancer
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04995523
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (
ARTEMIDE-01
)
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-TIGIT monoclonal antibody
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04686305
Advanced
Phase 1
Recruiting
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (
DL03
)
anti-ERBB2 antibody-drug conjugate
+ bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04612751
Advanced
Phase 1
Recruiting
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (
Tropion-Lung04
)
anti-Trop2 antibody-drug conjugate
platinum-based antineoplastic agent
+ bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-TIGIT monoclonal antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04305054
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (
3475-02B
)
anti-PD-1 monoclonal antibody
+ anti-TIGIT monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ anti-TIGIT monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ anti-TIGIT monoclonal antibody
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06267001
Curative
Phase 3
Active not recruiting
A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (
SKYSCRAPER-15
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
placebo
Non-small cell lung cancer
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05904886
Advanced
Phase 3
Active not recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (
SKYSCRAPER-14
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05845814
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B (
3475-04B
)
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
+ anti-TIGIT monoclonal antibody
Urothelial carcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
+ anti-TIGIT monoclonal antibody
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05665595
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010) (
7684A-010
)
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Tasman Oncology
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT05650203
Advanced
Phase 1
Withdrawn
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Combination With Toripalimab and JS006 in Patients With Advanced Malignancies (
JS009-002-I
)
anti-CD112R monoclonal antibody
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
Cancer
NCT05645692
Advanced
Phase 2
Not recruiting
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy (
BO44157
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05568095
Advanced
Phase 3
Active not recruiting
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma (
STAR-221
)
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
Adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05543629
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer (
CA115-001
)
anti-PD-1 monoclonal antibody
bispecific TIGIT/CD96 antibody
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05459129
Advanced
Phase 1 / Phase 2
Completed
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) (
CO43613
)
Atezolizumab
Carboplatin
Paclitaxel
Tiragolumab
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
platinum-based antineoplastic agent
taxane
+ anti-TIGIT monoclonal antibody
Head and neck squamous cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NCT05224141
Advanced
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (
7684A-008
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
topoisomerase inhibitor
Small-cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
NCT05116202
Advanced
Phase 1 / Phase 2
*paused
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (
BO43328
)
Atezolizumab
Ipilimumab
Nivolumab
RO7247669
Tiragolumab
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
+ anti-TIGIT monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05102214
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors (
HLX301-001
)
bispecific PD-L1/TIGIT antibody
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Active not recruiting (6)
Not yet recruiting (1)
Enrolling by invitation (1)
paused (1)
Withdrawn (1)
Not recruiting (1)
Terminated (1)
Completed (1)
*paused (1)
Unknown (1)
Recruitment Country and State
VIC (18)
NSW (17)
WA (13)
QLD (13)
SA (8)
NZ (6)
TAS (3)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (12)
Phase 2 (5)
Phase 3 (11)
Trial Type
Advanced (28)
Curative (4)
Cancer Therapy Class
PD-1/PD-L1
100%
TIGIT
100%
PD-1
78%
PD-L1
47%
LAG3
25%
VEGF
22%
CTLA4
16%
ERBB2
13%
PARP
9%
Trop2
6%
HIF2a
6%
KIT
6%
PDGFR
6%
VEGFR
6%
DPD
3%
orotate phosphoribosyltransferase
3%
CD73
3%
B7H4
3%
PARP1-selective
3%
CDK7
3%
EGFR
3%
KRAS
3%
KRAS G12C
3%
PI3Kalpha
3%
TIM3
3%
IL-6
3%
PPAR-alpha
3%
HPK1
3%
OX40
3%
RET
3%
VEGFR1
3%
VEGFR2
3%
VEGFR3
3%
AR
3%
CYP17A1
3%
androgen axis
3%
NECTIN4
3%
B7H3
3%
CD112R
3%
CD96
3%
Facility
3168 - Clayton - Monash Medical Centre (9)
6150 - Murdoch - Fiona Stanley Hospital (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
7000 - Hobart - Royal Hobart Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4870 - Cairns - Cairns Base Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4215 - Southport - Tasman Oncology (2)
2109 - North Ryde - Macquarie University Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4700 - Rockhampton - Rockhampton Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2031 - Randwick - Sydney Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
6009 - Nedlands - One Clinical Research (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
NA
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Hepatobiliary cancer
Urogenital cancer
Biliary tract cancer
Pancreatobiliary cancer
Hepatocellular carcinoma
Carcinoma
Melanoma
Head and neck cancer
Head and neck squamous cell carcinoma
Urothelial carcinoma
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
Oesophageal cancer
Atypical teratoid rhabdoid tumour
Bone cancer
Central nervous system cancer
Central nervous system primitive neuroectodermal tumour
Chordoma
Epithelioid sarcoma
Ewing family of tumours
Neurological cancer
Rhabdoid tumour
Sarcoma
Soft tissue sarcoma
Breast cancer
Endometrial cancer
Gynaecological cancer
Ovarian cancer
Squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Clear cell renal cell carcinoma
Kidney cancer
Adenocarcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy